trending Market Intelligence /marketintelligence/en/news-insights/trending/M7vZLkkyb2AfO8plxZr_rA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

Fuji Pharma Co. Ltd. acquired a 4.2% stake in Iceland-based biopharmaceutical company Alvotech for about $50 million.

Fuji Pharma and Alvotech entered into a partnership in November 2018 to develop and commercialize Alvotech's biosimilar portfolio in Japan. Under the partnership, Alvotech agreed to develop and supply multiple biosimilars, while Fuji will register and commercialize the assets in Japan.

According to Alvotech, the chairman of Tokyo-based Fuji Pharma will join the board of Alvotech following the investment.

Alvotech develops biosimilars to provide cost-competitive products to patients across the globe.